Early breast cancer

KISQALI^® (ribociclib tablets) is indicated in combination with an aromatase inhibitor (AI) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative stage II–III early breast cancer at high risk of recurrence. In pre/perimenopausal women, or men, the aromatase inhibitor should be combined with a luteinizing hormone-releasing hormone (LHRH) agonist.¹

NATALEE pivotal trial: A randomized, open-label, multicentre, phase III clinical study in pre/post-menopausal women, and men, with HR-positive, HER2-negative, stage II–III early breast cancer irrespective of nodal status, evaluating KISQALI^® in combination with an AI (letrozole or anastrozole) vs. AI alone.

Advanced or metastatic breast cancer

^PrKISQALI^® (ribociclib tablets) is indicated, in combination with:¹

• an aromatase inhibitor for the treatment of pre/perimenopausal or postmenopausal women, or men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer, as initial endocrine-based therapy;
  • in pre/perimenopausal women, or men, the endocrine therapy should be combined with a luteinizing hormone releasing hormone (LHRH) agonist.
• fulvestrant for the treatment of postmenopausal women, with HR-positive, HER2-negative advanced or metastatic breast cancer, as initial endocrine-based therapy or following disease progression on endocrine therapy.